Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like Ozempic and Wegovy (both of which were created by the same company).

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

Amy Schumer got brutally honest about the pros and cons she experienced while taking popular weight-loss drug Ozempic. On the Wednesday, January 29, installment of The Howard Stern Show, the actress revealed she took the medication "almost three years ago.

Once upon a time, Amy Schumer was one of the countless stars falling in line for the Ozempic craze, but, despite losing 30 pounds with the help of the Type 2 diabetes drug, the comedian had an overall "horrible experience" with it.